• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.

作者信息

Yang Xiaobo, Zhu Chengpei, Zhao Haitao

机构信息

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.

出版信息

Transl Lung Cancer Res. 2022 Oct;11(10):2164-2166. doi: 10.21037/tlcr-22-522.

DOI:10.21037/tlcr-22-522
PMID:36386458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9641038/
Abstract
摘要

相似文献

1
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.免疫检查点抑制剂联合酪氨酸激酶抑制剂是既往接受过治疗的伴有EGFR或ALK基因变异的晚期非小细胞肺癌的治疗选择。
Transl Lung Cancer Res. 2022 Oct;11(10):2164-2166. doi: 10.21037/tlcr-22-522.
2
Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.表皮生长因子受体和间变性淋巴瘤激酶抑制剂治疗的非小细胞肺癌患者甲状腺功能障碍：一项前瞻性队列研究结果。
Lung Cancer. 2021 Jan;151:16-19. doi: 10.1016/j.lungcan.2020.11.007. Epub 2020 Nov 18.
3
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.针对 EGFR 突变或 ALK 易位的非小细胞肺癌中的 PD-1/PD-L1 免疫检查点。
Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9.
4
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
5
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring or genetic aberration.卡瑞利珠单抗联合阿帕替尼在既往接受过治疗的携带或基因变异的晚期非小细胞肺癌患者中的疗效和安全性。
Transl Lung Cancer Res. 2022 Jun;11(6):964-974. doi: 10.21037/tlcr-22-22.
6
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
7
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
8
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.具有 ALK 重排突变的非小细胞肺癌患者的免疫微环境特征及其临床意义。
Front Immunol. 2022 Sep 8;13:974581. doi: 10.3389/fimmu.2022.974581. eCollection 2022.
9
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.在非小细胞肺癌中，将检查点抑制剂添加到靶向表皮生长因子受体/间变性淋巴瘤激酶的酪氨酸激酶抑制剂中：一种新的治疗策略。
Invest New Drugs. 2016 Dec;34(6):794-796. doi: 10.1007/s10637-016-0383-2. Epub 2016 Aug 25.
10
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.免疫检查点抑制剂单药治疗伴有重排的晚期非小细胞肺癌的疗效。
Int J Mol Sci. 2020 Apr 9;21(7):2623. doi: 10.3390/ijms21072623.

引用本文的文献

1
Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.第一届肿瘤学峰会会议记录：拉丁美洲分会，2023年5月19日至20日，巴西里约热内卢
Cancers (Basel). 2024 Sep 3;16(17):3063. doi: 10.3390/cancers16173063.
2
Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study.安罗替尼联合卡瑞利珠单抗治疗腹膜后软组织肉瘤的疗效和安全性：一项单中心回顾性队列研究
Ann Transl Med. 2023 Mar 15;11(5):212. doi: 10.21037/atm-23-460.

本文引用的文献

1
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring or genetic aberration.卡瑞利珠单抗联合阿帕替尼在既往接受过治疗的携带或基因变异的晚期非小细胞肺癌患者中的疗效和安全性。
Transl Lung Cancer Res. 2022 Jun;11(6):964-974. doi: 10.21037/tlcr-22-22.
2
Cancer statistics for the year 2020: An overview.2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.
3
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.表皮生长因子受体 (EGFR) 抑制剂在癌症靶向治疗中的进展综述。
Bioorg Chem. 2020 Jun;99:103811. doi: 10.1016/j.bioorg.2020.103811. Epub 2020 Apr 2.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Targeted drugs ramp up cancer mutability.靶向药物会加剧癌症的变异性。
Science. 2019 Dec 20;366(6472):1452-1453. doi: 10.1126/science.aaz9900.
6
Cancer treatment and survivorship statistics, 2019.2019 年癌症治疗与生存统计
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
7
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.表皮生长因子受体（EGFR）抑制剂治疗失败的 EGFR 突变、MET 因子失调的非小细胞肺癌患者中卡马替尼（INC280）联合吉非替尼的 Ib/II 期研究。
J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
8
Selective RET kinase inhibition for patients with RET-altered cancers.选择性 RET 激酶抑制剂治疗 RET 改变型癌症患者。
Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.
9
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
10
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.ALK/ROS1抑制剂PF-06463922克服ALK驱动的神经母细胞瘤对克唑替尼的原发性耐药。
Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.